Clinical Trial Update: A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment [Phase 1]

View source ↗

Summary

Phase Ib study evaluating AZD5462 on top of dapagliflozin in heart failure patients with moderate renal impairment was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure

Drugs mentioned

• AZD5462
• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Renal Impairment, Heart Failure | Phase 1 | Status: TERMINATED